ArticleChina CDC weekly2026
Pathogen Access and Benefit-Sharing: Can the WHO Pandemic Agreement Bridge the Equity Divide?
Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The adoption of the WHO Pandemic Agreement in May 2025 marks a pivotal shift toward institutionalizing global pandemic governance. Anchored in principles of equity, solidarity, and human rights, the agreement establishes a Pathogen Access and Benefit-Sharing (PABS) System, which aims to ensure equitable access to pandemic-related health products (PRHPs). However, operational ambiguities - particularly in defining pathogen scope, integrating traditional knowledge, enforcing manufacturer obligations, and coordinating with multilateral frameworks like the Convention on Biological Diversity and the Nagoya Protocol - pose significant implementation risks. Crucially, the agreement's effectiveness is intertwined with broader health system resilience. However, specific provisions for PABS integration within a strengthened health system architecture remain underdeveloped. Moreover, critical gaps persist regarding financing, compliance, One Health integration, digital governance, community engagement, and alignment with broader health systems. The success of the agreement hinges on resolving these gaps through subsequent protocols and sustained political commitment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.